PURE Bioscience Reaffirms Commitment to Providing Safe Drinking Water in Africa: Cooperative Project with BioTech Medical, LLC Focused on Delivering SDC Solution
Two Ounces of Silver-Based Formula Treat 200 Gallons of Water
SAN DIEGO, Calif., April 22, 2009 – PURE Bioscience (NASDAQ: PURE) announced today that it is working cooperatively with its distributor, BioTech Medical LLC, and several African countries to improve the quality of water with a new silver-based formula.
The technology, a proprietary new molecule created with ionic silver stabilized in citric acid, named silver dihydrogen citrate (SDC), is found to be safe, tasteless, and odorless and could eliminate the threat of dangerous water-born bacteria, such as cholera, which are prevalent in African countries. Initial testing concluded that as little as two ounces of SDC could treat 200 gallons of water in just minutes with no harm to the environment and no toxic side effects.
Andrea L. Goren, Executive Director of BioTech Medical LLC, said, “Compared with traditional antimicrobial chemicals, SDC has superior efficacy and reduced toxicity while mitigating the potential for microbial resistance. We are passionate about raising health standards through the distribution of SDC-based product, and we are proud to participate with PURE Bioscience in this critically important early-stage project.”
Globally, one billion people are without access to adequate water supply and 2.5 billion lack basic sanitation, leaving millions to die every year from otherwise preventable water-related diseases. Sanitation coverage is lowest in sub-Saharan Africa, where two-thirds of people do not have access to improved sanitation. For water, coverage remains below 60 per cent of the population in Sub-Saharan Africa.
Michael L. Krall, President and CEO of PURE Bioscience, said, “We are committed to helping Least Developed Countries in Africa and elsewhere improve the quality of their sanitation and drinking water. People living in rural areas are far less likely to have access to improved water and sanitation facilities than their urban compatriots. PURE Bioscience offers a cost-effective solution for developing countries that, once fully developed, could jump-start sanitation and drinking water supplies for these areas, thus providing a base for economic growth. We believe this is the first step for Least Developed Countries to transform into developed countries.
“Although this appears to be a long-term project for PURE, we are motivated to move as quickly as possible to deliver our SDC solution to people who need it most.” concluded Krall.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
About BioTech Medical, LLC
BioTech Medical LLC is a North Canton, Ohio based division of privately-held Suarez Corporation Industries (SCI), a leading international marketing company. SCI distributes hundreds of diversified products around the world and has established its success through product innovation and multi-channel marketing. BioTech Medical’s multiple business segments are each focused on the distribution of innovative healthcare products, including the SDC-based SpectraSan24 and Cruise Control hard surface disinfectants.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.